

## **BELGRAVIA provides update on its Dermatology Subsidiary**

TORONTO, Aug. 24, 2018 -- BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE: BLGV) (OTCQB: BLGVF) ("Belgravia" or the "Company") is pleased to announce that it has been actively advancing its Incubator Division, with targeted focus on developing active pharmaceutical ingredients based on cannabinoids and related natural molecules.

Mr. Mehdi Azodi, President and Chief Executive Officer of the Belgravia stated: "The incubator strategy entails financing promising early stage companies in industry sectors where there is clear secular growth and strong momentum. These characteristics provide bankable opportunities. These ventures do have early stage risk and development timing risk. Notwithstanding these risks, the Company and its consultants are committed to these opportune situations, with the goal of growing shareholder value through net asset value increases. Value may also be created by subsequent spin-outs in conjunction initial public offerings of the investees."

On May 11, 2018, Belgravia described the advancement of its Dermatology research and development in the application of cannabinoids for the treatment of unmet medical needs in skin pathologies. The company has been working with Dr. Sam Hanna, Chief Medical Officer. He is a well recognized dermatologist. The Company's advisors also include Dr. Shoaib Sheikh, an accomplished laparoscopic surgeon with training in health care delivery, and Belgravia Dermatology Director Sidney Himmel, who has experience as a biotechnology analyst and financier of biotechnology companies.

Mr. Sidney Himmel, Belgravia Dermatology Director, stated: "Belgravia Dermatology has established molecular targets for specific cannabinoids and terpenoids for the treatment of acne. Terpenoids or isoprenoids refer to a diverse class of naturally occurring organic chemicals derived from terpenes. Well known terpenoids include citral, menthol, camphor, ginkgolide, and bilobalide found in Ginkgo biloba. The company is evaluating specific delivery emulsion technologies. These technologies will be important for pharmacokinetic studies and the buttressing of intellectual property in the form of patents."

The Company has expended approximately \$150,000 to date on research and development, and anticipates increasing funding as the operations accelerate. Belgravia Dermatology is a wholly-owned subsidiary of the Company. Future financings at the subsidiary level may be undertaken on a partnering basis for financial optimization and to support the incorporation of value-added partners.

The Company is also pleased to also announce that it is in the process of expanding its portfolio of specialized cannabinoid and terpenoid molecular approaches for possible treatments in other specialized medical areas including urology and hepatology. Hepatology is the branch of medicine that deals with pathologies of the liver, gallbladder, biliary tree, and pancreas, and the management of those disorders.

### **About Belgravia**

Belgravia Capital International Inc. is focused on three core business divisions: Incubator, Investments, and Royalty & Management Services. The three divisions of Belgravia are high risk business ventures and expose shareholders to financial risks. The Incubator division provides capital to support the development of early stage companies in the Biotech/Healthcare, Technology, Resources and Medical sectors. Belgravia Holdings, the Investments division, invests in various private and public companies with a focus on value. Belgravia Royalty & Management Services has a royalty and fee income model. Further, the cash and investment asset base provides capital to support expansion on a selective basis.

For more information, please visit [www.belgraviacapital.ca](http://www.belgraviacapital.ca)

### **Forward-Looking Statements**

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements include statements that use forward-looking terminology such as "may", "will", "expect", "anticipate", "believe", "continue", "potential" or the negative thereof or other variations thereof or comparable terminology. Such forward-looking statements include, without limitation, statements regarding planned investment activities & related returns, the timing for completion of research and development activities, the potential value of royalties, and other statements that are not historical facts. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to, changes in market trends, the completion, results and timing of research undertaken by the Company, risks associated with resource assets, the impact of general economic conditions, commodity prices, industry conditions, dependence upon regulatory, environmental, and governmental approvals, and the uncertainty of obtaining additional financing. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.

### **For More Information, Please Contact:**

Mehdi Azodi, President & CEO

Belgravia Capital International Inc.  
(416) 779-3268  
[mazodi@blgv.ca](mailto:mazodi@blgv.ca)